Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets
C Kishimoto,
CS Crumpacker,
and
WH Abelmann
Charles A. Dana Research Institute, Beth Israel Hospital, Boston, Massachusetts 02215.
The efficacy of the synthetic nucleoside ribavirin in the therapy of experimental myocarditis caused by coxsackievirus B3 and its effects on peripheral and splenic lymphocyte subsets were investigated. Two week old male C3H/He mice were inoculated with coxsackievirus B3. Ribavirin was administered subcutaneously on days 0 to 15 (experiment I) and on days 4 to 15 (experiment II) in a dose of 200 (experiment I: Group 2, n = 10; experiment II: Group 5, n = 10) or 400 mg/kg per day (experiment I: Group 3, n = 10; experiment II: Group 6, n = 10). Control mice (experiment I: Group 1, n = 15; experiment II: Group 4, n = 14) received an injection of saline solution. In experiment I, mice treated with ribavirin survived significantly longer than did control mice (p = 0.005, Group 1 versus Group 2; p = 0.001, Group 1 versus Group 3). In experiment II, the survival rate on day 15 in ribavirin-treated mice was high compared with that in control mice (Group 4 = 14.3%, Group 5 = 20%, Group 6 = 50%). Myocardial viral titers on days 5 to 8 were significantly lower in ribavirin-treated mice of both experiments than in control mice.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
|
|
 
T.-C. Chen, H.-Y. Chang, P.-F. Lin, J.-H. Chern, J. T.-A. Hsu, C.-Y. Chang, and S.-R. Shih
Novel Antiviral Agent DTriP-22 Targets RNA-Dependent RNA Polymerase of Enterovirus 71
Antimicrob. Agents Chemother.,
July 1, 2009;
53(7):
2740 - 2747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.-C. Chen, K.-F. Weng, S.-C. Chang, J.-Y. Lin, P.-N. Huang, and S.-R. Shih
Development of antiviral agents for enteroviruses
J. Antimicrob. Chemother.,
December 1, 2008;
62(6):
1169 - 1173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z.-H. Li, C.-M. Li, P. Ling, F.-H. Shen, S.-H. Chen, C.-C. Liu, C.-K. Yu, and S.-H. Chen
Ribavirin Reduces Mortality in Enterovirus 71-Infected Mice by Decreasing Viral Replication
The Journal of Infectious Disease,
March 15, 2008;
197(6):
854 - 857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J K S Chia
The role of enterovirus in chronic fatigue syndrome
J. Clin. Pathol.,
November 1, 2005;
58(11):
1126 - 1132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. P. Liu and J. W. Mason
Advances in the Understanding of Myocarditis
Circulation,
August 28, 2001;
104(9):
1076 - 1082.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Lenzo, G. R. Shellam, and C. M. Lawson
Ganciclovir and Cidofovir Treatment of Cytomegalovirus-Induced Myocarditis in Mice
Antimicrob. Agents Chemother.,
May 1, 2001;
45(5):
1444 - 1449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Fohlman, K. Pauksen, T. Hyypia, G. Eggertsen, A. Ehrnst, N.G. Ilback, and G. Friman
Antiviral Treatment With WIN 54 954 Reduces Mortality in Murine Coxsackievirus B3 Myocarditis
Circulation,
November 1, 1996;
94(9):
2254 - 2259.
[Abstract]
[Full Text]
|
|
|
|
